Dimerix (DXB) Fundamentals 2026 — Revenue Analysis | SniperIQ
Dimerix (DXB) is a AU-listed Healthcare company in Biotechnology with a market capitalization of A
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Dimerix's market cap?
Dimerix (DXB) has a market capitalization of approximately A
How profitable is Dimerix?
Dimerix runs a net profit margin of -219.9%, a gross margin of 71.5%, and an operating margin of -548.1%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Dimerix generate?
Dimerix reported revenue of A
Does Dimerix pay a dividend?
Dimerix does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Dimerix financially healthy?
Dimerix carries a debt-to-equity ratio of -0.02x and a current ratio of 3.15x, with a market beta of 0.34. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Dimerix a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Dimerix (DXB) the key facts are: market cap A
Track Dimerix's full fundamentals live
Get Dimerix's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.